Skip to content

The AMD Experts

50196296_795957517416981_458178117475762176_n

Our Team

The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence.

Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.

The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.

Dr. Shawn Lewis1 Shawn Lewis, MD View all testimonials

Latest News & Upcoming Events

View More
Article: May 1, 2019 | Optometric Management

Diagnostic Devices

Dr. Laurie Sorrenson believes AMD patients should receive education about the diagnostic instruments and testing employed in practices for two reasons. Discover them now >>

Article: April 30, 2019 | The Ophthalmologist

Rethinking AMD

"An accidental discovery, an aging population, a new approach to healthcare; this is the story of MacuLogix."

Blog: March 25, 2019

Rediscovering the Retina

Five key takeaways from revisiting the anatomy and physiology of the retina. By Anne-Marie Lahr, OD.

Put Our Expertise to Work

Testing with AdaptDx

AdaptDx identifies impaired dark adaptation—the earliest warning sign of AMD.

Guiding AdaptDx Implementation

Each AdaptDx purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.